Product Images Dimethyl Fumarate

This text represents a graph showing the percentage of subjects with confirmed progression of disability over time for a placebo group and a group taking Dimethyl Fumarate 240 mg twice a day. Confirmed progression of disability is defined as an increase in EDSS score from a baseline score of 10 or greater, confirmed for 12 weeks, or a 15 point increase in EDSS score from a baseline of 0, confirmed for 12 weeks.*

Each capsule contains 20mg of Dimethyl Fumarate, prescribed for RxOnly. Take one capsule by mouth twice a day, preferably with delayed-release. Store the capsules at a temperature of 15°C to 100°C. Protect the capsules from light and keep them in the original container. The 120mg starter dose might be overcoded during packing. The capsules are manufactured by Cipla USA, Inc. and distributed by Cipla Laboratories Private Limited in Telangana, India. Swallow one capsule whole and there are 14 capsules in the container.*

This text is a medication label for Dimethyl Fumarate capsules with a dosage of 240mg, to be taken orally twice daily. The capsules should be stored in their original container at a temperature of 15°C to 30°C and protected from light. The medication is manufactured for Cipla USA, Inc. and the prescription requires swallowing one capsule whole each time. The label also contains important information such as the NDC number, usage directions, and manufacturing details.*

Dimethyl Fumarate Delayed-Release Capsules are available in a pack of 14 capsules manufactured by Cipla. Each capsule contains 20mg of fumarate. The recommended dosage is one capsule to be swallowed whole by mouth. The capsules are produced in the USA by Cipla at Independence Boulevard, Suite 390.*

This is a description of medicine identified by the NDC code 69097-323-03, named "Dimethyl Fumarate Delayed-Release Capsules". Each container has 60 capsules, and each contains 240 mg of Dimethyl Fumarate. The dosage requires personnel to take one capsule orally twice a day. It's essential to keep the capsules at 15°C to 30°C (59°F to 86°F), away from sunlight or artificial light, and in the original container. This drug is manufactured by Cipla, India, and sold by its subsidiary in the USA named Cipla USA, Inc., which is located in Warren, NJ. This medicine is only available with a valid prescription.*

This is a description of a medication with the brand name Dimethyl Fumarate. Each capsule of the medication contains 120 mg of dimethyl fumarate, and the dosage requires one capsule to be taken twice daily. This medication comes in a delayed-release capsule, and patients are advised to swallow it whole. The medication is manufactured by MSN Laboratories Private Limited, Telangana - 509 228, and distributed for Cipla USA, Inc. The packaging of the medication has information about the dosage and administration, and it's recommended to store it at 15°C to 30°C. The other information on the packaging includes the pharmacode, SAP code, package size, and contact information for support.*

This is a description of a medication called Dimethyl Fumarate Delayed-Release Capsules. The prescription contains 60 capsules with each capsule carrying 240mg of dimethyl fumarate. The dosage requires taking one capsule by mouth twice daily. The medicine should be stored between 15°C to 30°C, away from light, and must be dispensed inside its original package. The rest of the text are details about the manufacturer, dosage, administration, and support for the medication.*

This text contains information about a medication called Dimethyl Fumarate that comes in a 30-day starter pack with two bottles containing 14 and 46 capsules of 120 mg and 240 mg each, respectively. This medicine manufactured in India and marketed in the United States by Cipla, is used to treat multiple sclerosis. The document contains dosage and administration instructions, storage recommendations, and contact information for support. There is also a reference to the package insert for further details.*